 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H24N4O7S |
| Molar mass | 476.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Acefurtiamine (INN) is a vitamin B1 analog in a manner similar to the GABAergic activity of the thiamine derivative clomethiazole. [1] It functions as an analgesic agent at sufficient doses.[ medical citation needed ]
Clobetasol is a synthetic glucocorticoid corticosteroid. A propionate ester of clobetasol, clobetasol propionate, has also been marketed, and is far more widely used in comparison.
Fluprednidene, also known as fluprednylidene, is a synthetic glucocorticoid corticosteroid which was never marketed. An acetate ester of fluprednidene, fluprednidene acetate, in contrast, has been marketed.
Acefluranol, also known as 2,3-bis(3,4-diacetoxy-5-fluorophenyl)pentane, is a nonsteroidal antiestrogen of the stilbestrol group that was never marketed.
Butidrine (INN), or butedrine or butydrine, also known as hydrobutamine or idrobutamine, is a beta blocker related to pronethalol and propranolol that was developed in the 1960s. Similarly to certain other beta blockers, butidrine also possesses local anesthetic properties.
Inocoterone is a steroid-like nonsteroidal antiandrogen (NSAA) that was never marketed. An acetate ester, inocoterone acetate, shows greater antiandrogen activity and was developed, as a topical medication for the treatment of acne but showed only modest effectiveness in clinical trials and similarly was never marketed.
Fenethazine (INN), or phenethazine, is a first-generation antihistamine of the phenothiazine group. Promethazine and chlorpromazine, were derived from fenethazine. Fenethazine, in turn, was derived from phenbenzamine.
Nilestriol, also known as nylestriol, is a synthetic estrogen which was patented in 1971 and is marketed in China. It is the 3-cyclopentyl ether of ethinylestriol, and is also known as ethinylestriol cyclopentyl ether (EE3CPE). Nilestriol is a prodrug of ethinylestriol, and is a more potent estrogen in comparison. It is described as a slowly-metabolized, long-acting estrogen and derivative of estriol. Nilestriol was assessed in combination with levonorgestrel for the potential treatment of postmenopausal osteoporosis, but this formulation ultimately was not marketed.
Pentagestrone, also known as 17α-hydroxyprogesterone 3-cyclopentyl enol ether, is a steroidal progestin of the 17α-hydroxyprogesterone group that was never marketed. An acetate ester, pentagestrone acetate, has been marketed for clinical use. Pentagestrone was described in the literature in 1960.
Clogestone, also known as chlormadinol or as 3β,17α-dihydroxy-6-chloropregna-4,6-diene-20-one, is a steroidal progestin that was synthesized in 1964 and was investigated as a progestin-only contraceptive but was never marketed. A diacetate ester, clogestone acetate, also exists and similarly was never marketed.
Amadinone acetate, also known as 19-norchlormadinone acetate, is a steroidal progestin of the 19-norprogesterone and 17α-hydroxyprogesterone groups that was never marketed. It is the acetate ester of amadinone, which, similarly, was never marketed.
Ethinylestriol (EE3), or 17α-ethynylestriol, also known as 17α-ethynylestra-1,3,5(10)-triene-3,16α,17β-triol, is a synthetic estrogen which was never marketed. Nilestriol, the 3-cyclopentyl ether of ethinylestriol, is a prodrug of ethinylestriol, and is a more potent estrogen in comparison, but, in contrast to ethinylestriol, has been marketed. Ethinylestriol has been found to reduce the risk of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary cancer when given as a prophylactic in animal models, while other estrogens like ethinylestradiol and diethylstilbestrol were ineffective.
6,6-Difluoronorethisterone, also known as 6,6-difluoro-17α-ethynyl-19-nortestosterone or as 6,6-difluoro-17α-ethynylestr-4-en-17β-ol-3-one, is a steroidal progestin of the 19-nortestosterone group that was described in 1971 but was never marketed. It is a fluorinated derivative of norethisterone. The C17β acetate ester, 6,6-difluoronorethisterone acetate, has also been synthesized and described.
Clomifenoxide (INN), also known as clomifene N-oxide, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that is described as an antiestrogen and "gonad stimulant" and was never marketed. It is an active metabolite of clomifene.
Dacuronium bromide is an aminosteroid neuromuscular blocking agent which was never marketed. It acts as a competitive antagonist of the nicotinic acetylcholine receptor (nAChR).
Prednisolamate, also known as prednisolone 21-diethylaminoacetate, is a synthetic corticosteroid. It is or was a component of Etaproctene, which contains lidocaine, prednisolamate hydrochloride, and tetryzoline.
Cloticasone is a synthetic glucocorticoid corticosteroid which was never marketed.
Triclonide is a synthetic glucocorticoid corticosteroid which was never marketed.
Triamcinolone aminobenzal benzamidoisobutyrate is a synthetic glucocorticoid corticosteroid which is no longer marketed.
Sulfanitran is a sulfonamide antibiotic which is used in the poultry industry. It is a component of Novastat, Polystat, and Unistat, brand names of feed additives for chickens used to control Coccidioides spp.
Pinoxepin is an antipsychotic of the tricyclic group with a dibenzoxepin ring system which was developed in the 1960s but was never marketed. It was found in clinical trials to have effectiveness in the treatment of schizophrenia similar to that of chlorpromazine and thioridazine. The drug has marked sedative effects but causes relatively mild extrapyramidal symptoms.
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
